Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway

Margaret Kasner, Alexander E. Perl, Neal Flomenberg et al.|Blood|2012

Cited by 3